Worldwide, lung cancer is the leading cause of cancer death. Therapeutic options for non–small cell lung cancer (NSCLC) have changed significantly in recent years because of the evolving recognition of genetic abnormalities and the development of targeted therapies for these mutations.
Many NSCLC patients, however, present without targetable mutations.
In this ReCAP, Dr Luis L. Paz-Ares, of University Hospital, Madrid, Spain, reflects on first- and second-line treatment strategies for patients without apparent targetable genetic alterations, using immunotherapy as a single agent or in combination with chemotherapy.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Therapy for Patients With Non–Small Cell Lung Cancer in the Absence of Genomic Mutations - Medscape - Oct 30, 2020.
Comments